These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8189029)

  • 21. Management of inflammatory bowel disease. Proceedings of an international symposium on mesalazine. frankfurt, 23-25 March 1988.
    Scand J Gastroenterol Suppl; 1990; 172():1-68. PubMed ID: 2353167
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug therapy for inflammatory bowel disease: Part I.
    Linn FV; Peppercorn MA
    Am J Surg; 1992 Jul; 164(1):85-9. PubMed ID: 1626611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease.
    Kadiyala I; Jacobs D
    Recent Pat Drug Deliv Formul; 2014 Apr; 8(1):3-11. PubMed ID: 24111938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory bowel disease.
    Van Rosendaal GM
    CMAJ; 1989 Jul; 141(2):113-23; discussion 123-4. PubMed ID: 2568163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
    Ann Intern Med; 1996 Jan; 124(2):204-11. PubMed ID: 8533995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An alternative view of 5-ASA formulations.
    Rhodes J; Coles GA
    Gut; 1995 Apr; 36(4):639-40. PubMed ID: 7737577
    [No Abstract]   [Full Text] [Related]  

  • 27. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
    Christensen LA; Jacobsen BA
    Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is radical scavenging necessary in the treatment of inflammatory bowel disease?
    Allgayer H; Gugler R; Böhme P; Schmidt M; Höfer P; Kruis W
    Gastroenterology; 1991 Feb; 100(2):581-2. PubMed ID: 1985062
    [No Abstract]   [Full Text] [Related]  

  • 29. [5-ASA versus sulfasalazine].
    Varela E
    Acta Gastroenterol Latinoam; 1994; 25(5):317-9. PubMed ID: 7785405
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
    Baker DE
    Rev Gastroenterol Disord; 2005; 5(3):135-41. PubMed ID: 16127348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asacol: mesalazine for ulcerative colitis.
    Drug Ther Bull; 1986 May; 24(10):38-40. PubMed ID: 3709355
    [No Abstract]   [Full Text] [Related]  

  • 32. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature.
    Sviri S; Gafanovich I; Kramer MR; Tsvang E; Ben-Chetrit E
    J Clin Gastroenterol; 1997 Jan; 24(1):34-6. PubMed ID: 9013348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uncoated versus coated 5-aminosalicylic acid in Crohn's disease.
    Bossi A; Giuliani GE; Del Poggio P; Fenili D; Ragaini S
    Lancet; 1989 Feb; 1(8632):276. PubMed ID: 2563434
    [No Abstract]   [Full Text] [Related]  

  • 35. Update on the aminosalicylates: a promise fulfilled.
    Peppercorn MA
    Gastroenterology; 1988 Dec; 95(6):1677-80. PubMed ID: 2903113
    [No Abstract]   [Full Text] [Related]  

  • 36. Aminosalicylates: old and new.
    Hanauer SB
    Mt Sinai J Med; 1990 Oct; 57(5):283-7. PubMed ID: 1982892
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.
    Mardini HA; Lindsay DC; Deighton CM; Record CO
    Gut; 1987 Sep; 28(9):1084-9. PubMed ID: 3678967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?].
    Allgayer H; Klotz U; Böhne P; Schmidt M; Kruis W
    Z Gastroenterol; 1994 Nov; 32(11):647-50. PubMed ID: 7886975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.
    Lauritsen K
    Dan Med Bull; 1989 Sep; 36(4):378-93. PubMed ID: 2572403
    [No Abstract]   [Full Text] [Related]  

  • 40. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
    Ardizzone S; Petrillo M; Molteni P; Desideri S; Bianchi Porro G
    J Clin Gastroenterol; 1995 Dec; 21(4):287-9. PubMed ID: 8583101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.